Arum Kim, MD
Medicine and Rehabilitation Medicine
NYU School of Medicine
Director of the Supportive Oncology Program
Perlmutter Cancer Center
MedicalResearch.com: What is the background for this study?
Response: There is increasing interest in medical marijuana and its applications for patients with cancers. Despite increasing access, little is known regarding doses of cannabinoids – specifically tetrahydrocannabinol (THC) and cannabidiol (CBD), methods of drug delivery, and differences in patterns of use between cancer and non-cancer patients.
MedicalResearch.com Interview with:
Dr. Nicole Karcher, PhD Post-doctoral scholar with the NIMH Training in Clinical Sciences fellowship
Department of Psychiatry
Washington University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: For over fifteen years, researchers have debated the role that cannabis use plays in the development of both psychotic disorders as well as subthreshold psychotic symptoms, such as psychotic-like experiences (PLEs). There is still a lack of consensus regarding the nature of the association between cannabis use and psychosis risk, with some research finding evidence for genetic overlap, while other research finds evidence for potentially causal pathways.
The current study examined data from twins and siblings from two different samples, the U.S.-based Human Connectome Project and the Australian Twin Registry, with a total of 4,674 participants. Overall, psychotic-like experiences were associated with three separate cannabis use variables [frequent (≥100 times) use, a Cannabis Use Disorder diagnosis, and current cannabis use]. Furthermore, the current research found evidence for both shared genetic and individual-specific contributions to the association between PLEs and these three cannabis use variables. More specifically, while the association between cannabis use and psychotic-like experiences was largely attributable to shared genetic factors, cannabis users were more likely to endorse PLEs in comparison to the relative who used cannabis less.Continue reading →
MedicalResearch.com Interview with: David Plurad, MD
Los Angeles Biomedical Research Institute.
Medical Research: What are the main findings of the study?
Based on a survey of patients with traumatic brain injuries, a group of Los
Angeles Biomedical Research Institute researchers found those who tested
positive for tetrahydrocannabinol (THC), the active ingredient in marijuana, were more likely to survive than those who tested negative for the illicit substance.
We surveyed 446 patients who were admitted to a major urban hospital with
traumatic brain injuries between Jan. 1, 2010, and Dec. 31, 2012, who were
also tested for the presence of THC in their urine. We found 82 of the
patients had THC in their system. Of those, 2.4% died. Of the remaining
patients who didn’t have THC in their system, 11.5% died.
While most – but not all – the deaths in the study can be attributed to the
traumatic brain injury itself, it appears that both groups were similarly
injured. The similarities in the injuries between the two groups led to the
conclusion that testing positive for THC in the system is associated with a
decreased mortality in adult patients who have sustained traumatic brain
injuries. Continue reading →
Thank you for visiting MedicalResearch.com.
The information on this site is NOT intended as specific medical advice.
Please contact your health care provider with specific questions or concerns.
For suggestions or advertising information,
please contact Marie Benz at info@MedicalResearch.com